Viroblog

Archives

• 2022 (9)
  • May (3)
    • Wildfire’s Infectious Diseases Blog – ‘The Pathogenda’ Part 3
    • Human infection studies: Key considerations for challenge agent development and production
    • The Pathogenda - Infectuous Disease Report - May 2022
  • April (1)
    • Wildfire’s Infectious Diseases Blog – ‘The Pathogenda’ Part 2
  • March (2)
    • Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
    • Wildfire’s Infectious Diseases Blog – ‘The Pathogenda’
  • February (2)
    • EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
    • Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge
  • January (1)
    • hLab – Virology Laboratory Services
• 2021 (6)
  • November (1)
    • Human Challenge Trials as a tool in raising funding
  • July (2)
    • SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic
    • Don't be afraid of the FDA
  • April (1)
    • Rolling Reviews – a useful tool to speed up the regulatory review process
  • March (1)
    • Hot Topics – Vaccine Solutions for Tropical Diseases
  • January (1)
    • Accelerated regulatory pathway for pandemic vaccines
• 2020 (1)
  • September (1)
    • ERS International Congress 2020 Presentation: Experimental Respiratory Syncytial Virus Infection in Adults 60-75 years
• 2019 (9)
  • September (5)
    • Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics
    • A Key Endpoint in Viral Challenge Models of Asthma Exacerbations
    • hVIVO to present at upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain
    • Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model
    • THE HUMAN VIRAL CHALLENGE MODEL WITH A/PERTH/16/2009 H3N2A SYSTEMATIC ANALYSIS FROM FIVE CLINICAL STUDIES
  • July (1)
    • Join us! hVIVO presenting two posters and an oral presentation at the ISIRV Options X conference, Singapore, Asia, August 2019
  • April (2)
    • hVIVO is Gold Sponsor and presenter at World Vaccine Congress, Washington DC, USA April 2019
    • hVIVO and Imutex Limited to present at IVW 2019 conference, Edinburgh, Scotland, April
  • March (1)
    • hVIVO's Alex Mann making an oral presentation at ISRIV 1st Influenza Vaccine Group Meeting, Siena, Italy, March
• 2018 (12)
  • November (1)
    • View hVIVO's four scientific poster presentations from ISIRV RSV and ISIRV AVG conferences
  • October (3)
    • hVIVO making four poster presentations at ISIRV AVG 2018, Washington, D.C. USA, Nov 2018
    • hVIVO making poster presentations at ISIRV RSV 2018, Asheville, NC USA, Oct 2018
    • Scientific Paper 106 - Effect of pre-existing serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults
  • September (1)
    • Recap on hVIVO scientific poster at ERS 2018, Paris, France, Sept 2018
  • August (1)
    • hVIVO to present at ERS 2018, Paris, France
  • June (1)
    • View the hVIVO scientific poster at ATS 2018, San Diego, California USA
  • May (1)
    • hVIVO making poster presentation at ATS 2018, San Diego, California USA
  • April (1)
    • hVIVO’s Dr Rob Lambkin-Williams and Dr Anthony Gilbert presenting at Universal Influenza Vaccines 2018, Switzerland, April 2018
  • March (1)
    • hVIVO’s Dr Nicolas Noulin making oral presentation at World Vaccine Congress (“WVC 2018”), Washington DC USA, April
  • February (1)
    • The “History” of the Flu Vaccine From 1940 to 2030?
  • January (1)
    • Australian Flu Hits the Northern Hemisphere.
• 2017 (38)
  • December (1)
    • Here comes the flu.
  • July (1)
    • Recap on hVIVO scientific poster at ATS 2017, Washington D.C., May 2017
  • May (2)
    • Missed WVC US 2017? Not too late to view the hVIVO poster presentation
    • hVIVO’s John Efthimiou making poster presentation at ATS 2017, Washington, D.C. USA
  • March (11)
    • hVIVO’s Dr Rob Lambkin-Williams making two oral presentations at Influenza Vaccines for the World (“IVW 2017”), Lausanne, Switzerland, April 2017
    • hVIVO’s Dr Anthony Gilbert making oral presentation at World Vaccine Congress (“WVC 2017”), Washington DC USA, April 2017
    • Scientific paper 49 - An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo
    • Scientific paper 48 - Influenza virus infection in the second and third trimesters of pregnancy : a clinical and seroepidemiological study
    • Scientific paper 45 - Targeting influenza virus neuraminidase—a new strategy for antiviral therapy
    • Scientific paper 43 - Natural and ‘In vitro’ selected antigenic variants of influenza A virus (H2N2)
    • Scientific paper 40 - Amantadine in man and horse--can we learn from each other?
    • Scientific paper 39 - Viral drug resistance
    • Scientific paper 38 - Isolation of influenza A(H3N2) virus with "O"-->"D" phase variation
    • Scientific paper 33 - Electrophoretic Analysis of Nucleic Acids Isolated from Scrapie-infected Hamster Brain
    • Scientific paper 32 - Initial in vitro screening of drug candidates for their potential antiviral activities
  • February (22)
    • Scientific paper 28 - All rabbits immunized with type A influenza virons have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B
    • Scientific paper 27 - IgA, IgA subclasses, and secretory component levels in oral fluid collected from subjects after parental influenza vaccination
    • Scientific paper 26 - Attenuation of virulence in influenza B viral infection of volunteers
    • Scientific paper 22 - An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination
    • Scientific paper 21 - Antigenic and sequence analysis of H3 influenza virus haemagglutinins from pigs in Italy
    • Scientific paper 20 - Direct sequence determination of the influenza B HA-1 gene after PCR amplification of clinical specimens from an infected volunteer
    • Scientific paper 19 - Studies on the antibody response of mice and humans after immunization with potential influenza virus A (H1N1) vaccines
    • Scientific paper 16 - Concurrent antigenic analysis of recent epidemic influenza A and B viruses and quantitation of antibodies in population serosurveys in Italy
    • Scientific paper 15 - The haemagglutinins of influenza A (H1N1) viruses in the 'O' or 'D' phases exhibit biological and antigenic differences
    • Scientific paper 12 - Sequence analysis of the equine H7 influenza virus haemagglutinin gene
    • Scientific paper 11 - Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: Antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response
    • Scientific paper 10 (letter) - Amantadine for influenza A
    • Scientific paper 9 - Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition
    • Scientific paper 8 - Antigenic and biochemical studies of influenza viruses isolated in defined community epidemics have allowed the development of a new experimental inactivated vaccine
    • Scientific paper 7 - Detection of two antigenic subpopulations of A(H1N1) influenza viruses from pigs: Antigenic drift or interspecies transmission?
    • Scientific paper 6 - A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers
    • hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate
    • Scientific paper 5 - Genome and antigenic analysis of influenza A (H3N2) viruses isolated from an epidemic in a closed community of Carmelite nuns
    • Scientific paper 4 - Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule
    • Scientific paper 2 - Influenza viruses induce autoantibodies to a brain-specific 37-kDa protein in rabbit
    • Scientific paper 1 - Protein and nucleic acid analysis of influenza B viruses isolated in Italy in 1984
    • Scientific paper - The effective rate of influenza reassortment is limited during human infection
  • January (1)
    • Scientific paper - An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model
• 2016 (82)
  • December (1)
    • Scientific paper - A Tool for Investigating Asthma and COPD Exacerbations
  • November (8)
    • Recap on the hVIVO oral presentation at Flu 2016, San Francisco, October 2016
    • Scientific paper 110 - Efficacy and Safety of Treatment With an Anti-M2e Monoclonal Antibody in Experimental Human Influenza
    • Scientific paper 112 - Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge
    • Scientific paper 94 - Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
    • Scientific paper - A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness
    • Scientific paper 93 - Use of a Human Influenza Challenge Model to Assess Person-to-Person Transmission: Proof-of-Concept Study
    • Scientific paper 103 - Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection
    • hVIVO’s Dr Rob Lambkin-Williams making oral presentation at Human Antibodies & Hybridomas (“HAH 2016”), Belfast, November 2016
  • October (3)
    • hVIVO's Dr Anthony Gilbert to speak at Flu 2016, San Francisco at the end of October
    • hVIVO to Present at the 2016 BIO Investor Forum 18 October 2016, San Francisco USA
    • Missed RSV 2016 in Argentina? Not too late to view the hVIVO poster presentation
  • September (4)
    • hVIVO’s Dr Martin Johnson making oral presentation at World Vaccine Congress Europe, “WVC 2016”, Barcelona Spain, October 2016
    • Missed Options IX in Chicago ? Not too late to view the four hVIVO poster presentations
    • hVIVO making poster presentations at respiratory syncytial virus conference, ‘RSV 2016’, Patagonia Argentina, September 2016
    • hVIVO landmark asthma stratification initiative, supporting targeted therapy development, is underway
  • August (1)
    • hVIVO’s Alex Mann presenting asthma scientific poster at ERS 2016, London, September 2016
  • July (1)
    • hVIVO making significant number of poster presentations at influenza conference, Options IX, along with exhibition presence, Chicago USA, August 2016
  • June (2)
    • hVIVO confirms favourable results for PrEP Biopharm’s PrEP-001 Phase IIa influenza prophylaxis study
    • hVIVO’s Dr Nicolas Noulin will be presenting at “Virus-Like Particle & Nano-Particle Vaccines” Leiden, The Netherlands , June 2016
  • May (2)
    • hVIVO’s Dr Nicolas Noulin will be an active contributor to the debate during EDUFLUVAC, June 2016
    • Today, 20th May 2016, is International Clinical Trials Day !
  • April (5)
    • hVIVO announces initial results for PrEP Biopharm’s PrEP-001 look favourable in Phase IIa influenza prophylaxis study
    • hVIVO announces a joint venture investment with the SEEK Group to develop vaccines against flu and Zika infections
    • hVIVO’s John Efthimiou making poster presentation at ATS 2016, San Francisco, California USA
    • Scientific paper - The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.
    • Why do we need a cure for the common cold?
  • March (5)
    • Man Flu: “I told you I was ill”
    • hVIVO Poster Presentation at the 2016 AAAAI Annual Meeting - summary
    • hVIVO’s Melissa Wagner will be presenting two posters at Molecular Med Tri-Con, San Francisco, USA, March 2016
    • hVIVO’s Dr Rob Lambkin-Williams making 2 oral and 2 poster presentations at Macrae Foundation International Symposium on Respiratory Viral Infections, Lisbon, Portugal, March 2016
    • hVIVO is Gold Sponsor and presenter at World Vaccine Congress, USA March 2016
  • February (44)
    • The Spread of Zika virus
    • hVIVO’s Alex Mann making poster presentation at AAAAI , Los Angeles, California USA, March 2016
    • Scientific Paper 97: Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.
    • Scientific Paper 89 : A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.
    • Scientific Paper 107 : Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
    • Scientific Paper 78 : Preclinical in vitro activity of QR-435 against influenza A virus as a virucide and in paper masks for prevention of viral transmission.
    • Scientific Paper 79 : In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection.
    • Scientific Paper 72 : A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV.
    • Scientific Paper 74 : Scientific lessons from the first influenza pandemic of the 20th century.
    • Scientific Paper 75 : Influenza is now a preventable disease
    • Scientific Paper 63 : Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
    • Scientific Paper 62 : Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine.
    • Scientific paper 68 - A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
    • Scientific Paper 84 : A plant-produced influenza subunit vaccine protects ferrets against virus challenge.
    • Scientific Paper 73 : Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.
    • Scientific Paper 65 : Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
    • Scientific Paper 50 : Rapid antibody response to influenza vaccination in "at risk" groups.
    • Scientific Paper 66 : Human genetics and responses to influenza vaccination: clinical implications.
    • Scientific Paper 23 : Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift.
    • Scientific Paper 34 : Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions.
    • Scientific Paper 57 : The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
    • Scientific Paper 56 : Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine.
    • Scientific Paper 55 : Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
    • Scientific Paper 88 : Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans.
    • Scientific Paper 101 : A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2.
    • Scientific Paper 96 : Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.
    • Scientific Paper 86 : Animal models in influenza vaccine testing.
    • Scientific Paper 80 : Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection.
    • Scientific Paper 109 : A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    • Scientific Paper 77 : The threat of avian influenza H5N1: 'do we have the tools for the job'?
    • Scientific Paper 99 : Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination.
    • Scientific Paper 98 : Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections.
    • Scientific Paper 105 : Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.
    • Scientific Paper 93 : Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study.
    • Scientific Paper 108 : Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM)
    • Scientific Paper 87 : DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial.
    • Scientific Paper 104 : Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.
    • Scientific Paper 83 : Flu - effect of vaccine in elderly care home residents: a randomized trial.
    • Scientific Paper 114 : Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
    • Scientific Paper 91 : Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    • Scientific Paper 92 : A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.
    • Scientific Paper 90 : Viral load drives disease in humans experimentally infected with respiratory syncytial virus
    • Scientific Paper 102 : Oral GS-5806 activity in a respiratory syncytial virus challenge study.
    • Scientific Paper 89 : A randomised, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.
  • January (6)
    • Scientific paper 115 - New hVIVO co-authored paper published in Oxford Journals “Open Forum Infectious Diseases” : “A genomic signature of influenza infection shows potential for presymptomatic detection, guiding early therapy, and monitoring clinical responses”
    • Germany Confirms Five Zika Virus Cases
    • WHO leader: Zika virus 'spreading explosively'
    • Scientific paper 114 - New hVIVO authored paper published in PLOS One: "Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Challenge Model"
    • Beware Influenza, The Silent Killer - Forbes
    • China reports human H7N9 avian influenza infection in Shanghai man | Outbreak News Today
• 2015 (137)
  • December (6)
    • WHO influenza update - 28/12/15
    • 'top trending health symptom on Google in 2015'
    • Mers virus vaccine 'a step closer'
    • Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial | Vaccines | News Channels
    • Partnership Redefines the Patient Recruitment Process to Improve Efficiencies and Accelerate Time to Market
    • Motavizumab reduces RSV hospitalizations in Native American infants
  • November (13)
    • Influenza-Associated Excess Mortality in South Korea
    • Press Announcements > FDA approves first seasonal influenza vaccine containing an adjuvant
    • Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
    • Sanofi Pasteur shares universal influenza vaccine research | Vaccine News
    • RSV MUCOSAL VACCINE - KIDO HIROSHI
    • Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations | European Respiratory Society
    • WHO | Influenza update - 19/10/15
    • VBI Vaccines to Present Update and New Data Supporting its RSV and CMV Vaccine Programs at the World Vaccine Congress Europe - NASDAQ.com
    • Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kindgom
    • Join us! hVIVO to sponsor RSV Vaccines for the World in California, USA, November 2015
    • hVIVO invests in PrEP Biopharm Limited to further develop new prophylactic treatment
    • Reference "Influence of Statins on Influenza Vaccine Response..."
    • Influenza Vaccine Less Effective in Seniors Taking Statins | Guardian Liberty Voice
  • October (9)
    • BMC Infectious Diseases | Full text | Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom
    • Quantifying the risk of pandemic influenza virus evolution by mutation and re-assortment — ScienceDirect
    • LONDON: Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference | Business Wire | Rock Hill Herald Online
    • WHO | Monthly Risk Assessment Summary
    • hVIVO poster presentation at Influenza Vaccines for the World event (IVW September 2015)
    • Visterra Wins Up-to-$204.5M BARDA Contract; Reports Positive Phase IIa Results
    • hVIVO is Gold Sponsor at World Vaccine Congress Europe, Madrid in November 2015
    • hVIVO poster presentation at ERS 2015 (European Respiratory Society International Congress) September 2015
    • 2000th hVIVO “FluCamp “ volunteer milestone achieved and marked with a donation to the Whitechapel Mission
  • September (8)
    • Controversies in medicine: the rise and fall of the challenge to Tamiflu
    • Join us! hVIVO’s Dr Rob Lambkin-Williams, Dr Anthony Gilbert, and Dr Daryl Borley speaking at the Influenza Vaccines for the World, Portugal, October 2015
    • Beat Asthma: Plant a Tree | You, Me and Medicine
    • Novavax RSV F vaccine trial for women shows promise | Vaccine News
    • Viral infection: Stemming influenza viruses : Nature Reviews Microbiology : Nature Publishing Group
    • hVIVO’s Dr Ganesh Balaratnam and Dr Daniel Fullen making poster presentation at The European Respiratory Society (ERS) International Congress 2015, Amsterdam, September 2015
    • Respiratory Syncytial Virus (RSV) infections Linked To Respiratory Failure In - Medical Research News and Interviews on MedicalResearch.com (blog)
    • Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
  • August (12)
    • Favorites
    • Stool screening of Syrian refugees and asylum seekers in Germany, 2013/2014: Identification of Sabin like polioviruses — ScienceDirect
    • ERJ | Mobile
    • Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing — ScienceDirect
    • Loading
    • Vaccine for Mers 'looks promising'
    • Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains - FierceBiotech
    • Is it 'man flu'? Is it 'woman flu'? The lowdown on influenza - Sydney Morning Herald
    • Additional hVIVO speaker at International Conference on Influenza, London, August 2015
    • Assessing coughing-induced influenza droplet transmission and implications for infection risk... - Abstract - Europe PubMed Central
    • Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion F Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine
    • Novavax (NVAX) Announces Seasonal Influenza VLP Met Immunogenicity Targets in ... - StreetInsider.com
  • July (9)
    • Reinventing the Common Cold Institute for the 21st Century
    • New Flu Vaccine May Soon Cover All Strains Of Influenza : LIFE : Tech Times - Tech Times
    • VACCINE AGAINST RSV - Radosevic, Katarina
    • What adaptive changes in hemagglutinin and neuraminidase are necessary for emergence of pandemic influenza virus from its avian precursor? - Springer
    • Favorites
    • A review of respiratory viruses in under 5s
    • NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11 - MarketWatch
    • hVIVO’s Dr Anthony Gilbert speaking at International Conference on Influenza, London, August 2015
    • WHO | Influenza update - 29/06/15
  • June (10)
    • Human bocavirus infection as a cause of severe acute respiratory tract infection in children — ScienceDirect
    • Thorax | Mobile
    • 22,000 asthma sufferers prescribed potentially deadly medication - Telegraph
    • Globally, influenza activity has decreased from its peak of influenza activity in early 2015 to low levels.
    • South Korea MERS outbreak: Interest
    • Fifth Person Dies Of MERS Virus In South Korea
    • South Korea to track mobile phones to enforce Mers virus quarantine rules
    • MERS, SARS, Ebola: How dangerous are they?
    • Communication gaps fuel MERS worries in Korea | Science/AAAS | News
    • WHO | Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season
  • May (24)
    • Mers case brings back memories of Hong Kong's Sars outbreak | South China Morning Post
    • Mers spreads
    • New universal influenza vaccines
    • Soon, a single flu shot may offer universal immunity! - BioSpectrum Asia
    • Oseltamivir reduces clinical illness in households in Bangladesh - The Lancet Infectious Diseases
    • Asthma patients showed greater bronchial mucosal inflammatory response to rhinovirus infection | Healio Mobile
    • Favorites
    • What We Have Learned of the Influenza A pH1N1 2009/10 pandemic: High Clinical Impact of Human Metapneumovirus and Respiratory Syncytial Virus in Hosp... - PubMed - NCBI
    • Favorites
    • Vaccines developed for H5N1, H7N9 avian influenza strains
    • Geocoding can help spot influenza outbreaks
    • Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. - PubMed - NCBI
    • Evolution of equine influenza led to canine offshoot which could mix with human influenza | Science Codex
    • Jimmunol
    • The Viral Network: A Pathography of the H1N1 Influenza Pandemic
    • Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults — ScienceDirect
    • WHO | Influenza update - 18/05/15
    • See you there! hVIVO’s Dr Rob Lambkin-Williams speaking at the International Conference on Flu
    • WHO | Human infection with avian influenza A(H7N9) virus – China - 14/05/15
    • Join Us! hVIVO's Dr Anthony Gilbert speaking at 4th ISIRV-AVG Conference
    • Antiviral medicines for influenza should not be prescribed | Notice-board | Pharmaceutical Journal
    • Jnl Inf Dis
    • Emergence of multidrug resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir
    • Avian influenza puts Thanksgiving at risk
  • April (11)
    • 2014 Annual Report and Financial Statements
    • Retroscreen Virology is proud to announce corporate name change to hVIVO to reflect pioneering efforts in human disease models
    • Planning for a cohort study to investigate the impact and management of influenza in pregnancy... - Abstract - Europe PubMed Central
    • Retroscreen Virology appoints Reid Tripp as Executive Vice President Business Development and Marketing
    • Quadrivalent influenza vaccine shows superior immunogenicity vs. trivalent vaccine in young children | Healio Mobile
    • Challenges in developing a cross-serotype rhinovirus vaccine
    • RSV, an on-going medical dilemma: an expert commentary on RSV prophylactic and therapeutic pharmaceuticals currently in clinical trials - Broadbent - Influenza and Other Respiratory Viruses - Wiley Online Library
    • Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults — NEJM
    • Estimating influenza attack rates in the United States using a participatory cohort : Scientific Reports : Nature Publishing Group
    • No such thing as Man Flu
    • Glaucoma treatment: by the highest level of evidence - The Lancet
  • March (11)
    • Seasonal influenza vaccination rates must be tackled at EU level | The Parliament Magazine
    • Flu vaccination during pregnancy is safe an excellent review article.
    • Low 2012-13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses.
    • Man Flu - myth or reality?
    • Microneedle patch may increase influenza immunization rate | Vaccine News Daily
    • The Viroblog 2.0
    • Influenza Type B overtakes A in Colorado during 2015, but still well below peak - The Denver Channel
    • Can universal vaccines knock out 'slowpoke' flu? - Futurity
    • WHO | Human infection with avian influenza A(H7N9) virus – China - 11/03/15
    • Influenza hits older adults hard this season | American Pharmacists Association
    • Retroscreen Medical Director attends XVII International Symposium on Respiratory Viral Infections, Canada 2015
  • February (13)
    • Strains of swine flu need universal vaccine | mydigitalfc.com
    • Epigenetic study highlights drug targets for allergies and asthma
    • Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan
    • Vaxin acquires Immune Targeting Systems in all-stock deal | BioPrepWatch.com
    • Flu Scan for Feb 17, 2014 | CIDRAP
    • Key to blocking influenza virus may lie in a cell's own machinery
    • Flu Season 2015: Influenza-Related Illnesses Tied To Surge In Hospital - International Business Times
    • ESWI (the flu community) news bulletin
    • CDC issues travel notice for China due to H7N9 avian influenza | Outbreak News Today
    • Flu Jab Found To Work In Just 3% Of Cases
    • Tamiflu DOES halt the spread of influenza, major review finds - Telegraph.co.uk
    • Higher death rate 'driven by flu' - BBC News
    • The Tamiflu fiasco and lessons learnt Gupta YK, Meenu M, Mohan P - Indian J Pharmacol
  • January (11)
    • Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials - The Lancet
    • Retroscreen Virology Senior Medical Director to speak at World Vaccine Congress USA 2015
    • Stuff
    • Study maps travel of H7 influenza genes
    • Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine - MarketWatch
    • Seasonal Influenza Vaccine Only 23% Effective This Year
    • Influenza Vaccine May Protect Against Guillain-Barre Syndrome
    • GEN | News Highlights:Brain Protein May Lead to Novel Flu Therapies
    • Order Antivirals Before Influenza Is Lab-Confirmed, CDC Says
    • BC 2015 influenza outbreak approaching 10-year maximum for medical visits - CBC.ca
    • Flu shot won't protect against influenza A - WBNG-TV
• 2014 (160)
  • December (5)
    • Influenza walloping schools in South, Midwest
    • Beware the approaching silent killer influenza
    • Flu: What a Bad Influenza Season Could Cost the U.S. Economy - Businessweek
    • What you don’t know about RSV could hurt your baby - The Washington Post
    • China reports human H7N9 avian influenza cases from Shanghai, Guangdong - National infectious disease | Examiner.com
  • November (4)
    • Halting the hijacker: Cellular targets to thwart influenza virus infection
    • Novavax (NVAX) Receives FDA Fast-Track Designation for RSV F Vaccine Candidate
    • Retroscreen Virology Chief Scientist to speak at Respiratory Syncytial Virus Symposium 2014
    • Influenza, a Familiar Virus, Requires Attention, Too - New York Times
  • October (14)
    • U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM) Nasdaq:NVAX
    • Google data could improve forecasting of influenza levels
    • Australia's CSL buys Novartis influenza vaccine unit for $275 million
    • Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26 Nasdaq:NVAX
    • Vaxart's Tablet Vaccine for H1N1 Influenza Generates Protective Immunity ... - FierceVaccines
    • Throwback Thursday | The 1918 Influenza Pandemic - New York Times (blog)
    • Efficacy and Safety of Treatment with an Anti-M2e Monoclonal Antibody in Experimental Human Influenza
    • Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects - MarketWatch
    • Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award
    • 'Virological penicillin': Plant MIR2911 directly targets influenza A viruses
    • Visterra bringing influenza immunotherapy into Phase 2 with $30M cash influx
    • Older Folks and Influenza: High Dose Vaccine 24% More Effective
    • Solving the mystery of why colds cause asthma attacks - Medical News Today
    • J and J purchase Alios
  • September (22)
    • Retroscreen presenting at "Human Challenge Trials in Vaccine Development"
    • Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - September 24, 2014 - Zacks.com
    • TREATMENT WITH ORAL ALS-008176, A NUCLEOSIDE ANALOG, RAPIDLY REDUCES RSV VIRAL LOAD AND CLINICAL DISEASE SEVERITY IN A HEALTHY VOLUNTEER CHALLENGE STUDY
    • CABINET // Virus Camp
    • Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women - MarketWatch
    • Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study
    • Using the Human Viral Challenge Model to design subsequent field based studies
    • Virus Shedding from the nasal mucosa is closely correlated with illness severity in the Human Viral Challenge Model
    • A mini-antibody with broad antiviral activity chews up viral DNA and RNA
    • Virus Outbreak Sends 1,000 Kids To Hospital
    • Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection
    • Biomed Central PDF
    • CDC publishes ACIP recommendations for 2014-2015 seasonal influenza vaccines | Healio Mobile
    • CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical Results at ICAAC - MarketWatch
    • Influenza vaccination in pregnancy protects both mother and infant | 2 Minute Medicine
    • USGS Release: Avian Flu in Seals Could Infect People (9/3/2014 5:00:00 AM)
    • GEN | News Highlights: Sanofi Pasteur Dengue Vaccine Aces Second Phase III Trial
    • Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection
    • BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting - MarketWatch
    • Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A Flu B and RSV Infection - News Press Release | PharmiWeb.com
    • RETROSCREEN EXHIBITING AT ERS 2014 MUNICH IN SEPTEMBER
    • Research will help flu fight | Scoop News
  • August (13)
    • Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
    • No benefit seen with IV peramivir in hospitalized patients with influenza | Healio Mobile
    • Retroscreen announces results from hVIVO viral challenge study on respiratory syncytial virus
    • FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector - MarketWatch
    • VIRAPOPS2 supports the influenza virus reassortments
    • Influenza: High-Dose Vaccine Decreases Flu in Older Adults - Medscape
    • Influenza: How the Great War helped create the greatest pandemic ever known - The Guardian
    • Retroscreen partners with ERT for centralised ECG services in hVIVO challenge studies
    • Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New England Journal of Medicine
    • WHO | Influenza update - 11/08/14
    • Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim - WSJ.com
    • Biota's influenza drug fails in mid-stage study
    • Key narcolepsy–influenza vaccine findings retracted | Science/AAAS | News
  • July (11)
    • Influenza: How the Great War helped create the greatest pandemic ever known | GrrlScientist | Science | The Guardian
    • Retroscreen conducts landmark hVIVO Human Challenge Model Study of AL-8176 in RSV for Alios BioPharma
    • New treatment fights common infant virus
    • Promising New Influenza Drug Reduces Flu Symptoms and Viral SheddingMedical Research News and Interviews: MedicalResearch.com
    • Potential New Flu Drugs Target Immune Response, Not Virus
    • Members of previously uncontacted tribe infected with flu | Science/AAAS | News
    • Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza - FierceBiotech
    • Spatial-temporal excess mortality patterns of the 1918-1919 influenza pandemic in Spain
    • AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV Antibody - MarketWatch
    • Africa Battles To Stop Deadly Spread Of Ebola
    • CDC recommends AstraZeneca influenza vaccine | Vaccine News Daily
  • June (11)
    • Asthma patients showed greater bronchial mucosal inflammatory response to rhinovirus infection | Healio Mobile
    • Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A - MarketWatch
    • U.S. Biomedical Advanced Research and Development Authority (BARDA) Extends Contract with Protein Sciences Corporation - MarketWatch
    • Computation leads to better understanding of influenza virus replication | Science Codex
    • Start of hVIVO Challenge Study in Asthma
    • SARS enzyme finding could help advance MERS vaccine - FierceVaccines
    • Deadly Flu Strain Created In 'Crazy' Lab Study
    • Everyone Benefits When Hospital Workers Get Flu Shots
    • Four Cases of Human Infection With H7N9 Virus are Reported to WHO
    • TechnoVax Awarded NIH Grant to Develop a VLP based Respiratory Syncytial Virus (RSV) Vaccine - MarketWatch
    • BBC News - Mers virus: Saudi Arabia raises death toll to 282
  • May (26)
    • Protein Sciences Partners File for Marketing Approval of Flublok® Influenza Vaccine in Japan - MarketWatch
    • Immunity from inactivated seasonal influenza vaccine decreased after one year | Healio Mobile
    • Breakthrough in RSV Research to Help Infected Children
    • San Diego Teen To Present Influenza Research At White House | KPBS
    • Antivirals for influenza: where now for clinical prac... [Lancet. 2014] - PubMed - NCBI
    • Gilead's RSV drug clears mid-stage trial - PMLiVE
    • BBC News: Immune children aid malaria fight
    • COMMENTARY: Protecting health workers from airborne MERS-CoV—learning from SARS | CIDRAP
    • Flu and the animal interface an update
    • No difference in severity, outcomes between influenza A and B - Healio
    • Retroscreen exhibiting its hVIVO platform for accelerated drug development at American Thoracic Society International Conference 2014
    • Where Do Scary Diseases Like SARS and MERS Come From? Animals - Forbes
    • Second U.S. case of MERS confirmed
    • The World Today - SARS-like virus spreads across Middle East 12/05/2014
    • One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response - WSJ.com
    • IL-27 Balances The Immune Response To Influenza And Reduces Lung Damage - Health News - redOrbit
    • Unusual new penguin flu found in Antarctica - Yahoo News UK
    • WHO warns of risk to Syrian refugees as Mers virus cases increase sharply | Science | The Guardian
    • H1N1 influenza vaccine for pregnant women did not affect unborn children - The Information Daily.com
    • UTMB awarded $4.4M to develop universal flu vaccine
    • Mers vaccine helps mice fight off deadly virus
    • Secret of the 1918 Spanish flu epidemic uncovered - Daily Mail
    • AstraZeneca's MedImmune Specialty Care to Present Eleven Abstracts on Influenza, RSV at Upcoming Annual Pediatric Academic Societies Meeting - WSJ.com
    • Warning As Mers Coronavirus Lands In UK
    • Unusual Mortality Pattern of 1918 Influenza a Virus - Watching the Watchers
    • Secret of the 1918 Spanish flu epidemic uncovered - Daily Mail
  • April (9)
    • Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age - MarketWatch
    • SARS-Like MERS Virus Spreads to New Countries - ABC News
    • JCI - Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection
    • Healthcare Workers Knowledge About Influenza Transmission is Lacking
    • Sharp jump in SARS cases - World News - Castanet.net
    • Novel stapled peptide nanoparticle combination prevents RSV infection, study finds Science Codex
    • Researcher reviews influenza, bacterial superinfections in Nature Reviews Microbiology
    • MERS-CoV - Eastern Mediterranean (31): Saudi Arabia, Malaysia, Philippines
    • Retroscreen speaking and exhibiting at 2nd Vaccine Research Summit 2014
  • March (16)
    • iBio Receives Patent Allowances for Pandemic Influenza Therapeutics - WSJ.com
    • WHO: Six New Cases Of Human H7N9 Infection Reported In China
    • TB: Humans Catch Disease From Domestic Cats
    • Study suggests that self-administration of influenza vaccine may be feasible with microneedle patch
    • Why Google Flu Is A Failure - Forbes
    • Twitter effectively tracks influenza trends in New York: Study : LIFE : Tech Times
    • London study finds 77 percent of influenza infections are asymptomatic
    • HPA - National Influenza Report - 20/03/14
    • 17 percent of people with confirmed influenza visit the doctor - UPI.com
    • 'Vigorous exercise' cuts flu risk
    • Google's flu tracker: When big data went wrong, and why | ITProPortal.com
    • WHO | Monthly Risk Assessment Summary
    • Deadly H7N9 influenza reaches city’s borders | Macau Business Daily
    • Development of an Adenoviral-based RSV Vaccine: Preclinical Evaluation of Efficacy, Immunogenicity, and Enhanced Disease in a Cotton Rat Model
    • Avian-origin influenza A(H7N9) infection in inf... [J Infect Dis. 2014] - PubMed - NCBI
    • Influenza Origins Connected to Wrong Animal [Video] - Guardian Liberty Voice
  • February (12)
    • Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA - MarketWatch
    • Vietnam on high alert over flu risk : Nature News & Comment
    • A predictive fitness model for influenza
    • Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants
    • Saudi Arabia reports another death from SARS-like virus; 61 dead | CTV News
    • New vaccine policy for fatal virus « The Boar The Boar
    • HPA - National Influenza Report - 20/02/14
    • BBC News: New strain of 'deadly' bird flu
    • H7N9 avian influenza concerns escalate in China | Business, Political, and Cultural News in Fort Smith and Northwest Arkansas
    • Respiratory syncytial virus vaccine tested in Halifax clinic - Nova Scotia - CBC News
    • Human infection with avian influenza A(H5N1) viruses
    • Pandemic A/H1N1 influenza vaccination during pregnancy: A comparative study using the EFEMERIS database
  • January (17)
    • More H7N9 cases, 2 deaths, reported in mainland China, Hong Kong | Healio Mobile
    • Virus-Specific Antibody Secreting Cell, Memory B-cell, and Sero-Antibody Responses in the Human Influenza Challenge Model.
    • Intranasal vaccine protects mice against West Nile infection
    • Fever-reducing medications may contribute to spread of influenza | Vaccine News Daily
    • WHO | Influenza update - 27/01/14
    • Korea Confirms Detection of Highly Pathogenic Avian Influenza - The Poultry Site
    • Could cold meds help spread the flu? - NBC News.com
    • Fight the Flu, Hurt Society? | Science/AAAS | News
    • Influenza cases are increasing in the UK
    • Mark Kendall: Demo: A needle-free vaccine patch that's safer and way cheaper | Video on TED.com
    • WHO | Human infection with avian influenza A(H7N9) virus - update
    • Potential treatment for drug-resistant H7N9 influenza virus
    • WHO | Influenza update - 13/01/14
    • BBC News: First H5N1 death in North America
    • Vaxart’s Oral H1N1 Influenza Vaccine Generates Protective Immunity
    • HPA - National Influenza Report - 09/01/14
    • Influenza activity climbing in London and Middlesex | CTV London News
• 2013 (1)
  • October (1)
    • Scientific paper - Virus-induced exacerbations in asthma and COPD.